FDA
-
-
-
-
-
-
-
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
-
-
-
-
-
-
-
Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
-
-
-
-
-
-
-
BioTime Reports First Quarter Results and Recent Corporate Accomplishments
-
-
-
-
-
-
-
Pre-Open Movers 03/01: (NVAX) (DDD) (HIIQ) Higher; (PTLA) (PDCO) (BOX) Lower (more...)
-
-
-
-
-
-
-
Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study
-
-
-
-
-
-
-
Asterias (AST) Announced 12-month Data from Efficacy Cohort in Phase 1/2a SCiStar Study of AST-OPC1; Granted RMAT
-
-
-
-
-
-
-
Preclinical Data Published in Peer-Reviewed Journal Stem Cells Translational Medicine Provides Scientific Framework for Asterias’ AST-OPC1 for the Treatment of Subacute Cervical Spinal Cord Injury
-
322,248 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

